Lifecore Biomedical (LFCR) Competitors $8.03 -0.01 (-0.12%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LFCR vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHCShould you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Lifecore Biomedical vs. Its Competitors Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health Lifecore Biomedical (NASDAQ:LFCR) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Do analysts prefer LFCR or GPCR? Lifecore Biomedical currently has a consensus target price of $8.00, suggesting a potential downside of 0.37%. Structure Therapeutics has a consensus target price of $76.17, suggesting a potential upside of 269.40%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in LFCR or GPCR? 83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor LFCR or GPCR? In the previous week, Structure Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for Structure Therapeutics and 0 mentions for Lifecore Biomedical. Structure Therapeutics' average media sentiment score of 1.02 beat Lifecore Biomedical's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lifecore Biomedical Neutral Structure Therapeutics Positive Is LFCR or GPCR more profitable? Structure Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -35.90%. Structure Therapeutics' return on equity of -16.35% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-35.90% -551.09% -13.89% Structure Therapeutics N/A -16.35%-15.71% Which has more volatility and risk, LFCR or GPCR? Lifecore Biomedical has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, indicating that its stock price is 287% less volatile than the S&P 500. Which has preferable earnings and valuation, LFCR or GPCR? Lifecore Biomedical has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.26M2.32$12.01M-$1.45-5.54Structure TherapeuticsN/AN/A-$122.53M-$0.87-23.70 SummaryStructure Therapeutics beats Lifecore Biomedical on 9 of the 15 factors compared between the two stocks. Get Lifecore Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFCR vs. The Competition Export to ExcelMetricLifecore BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$297.68M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-5.5421.4227.5020.21Price / Sales2.32281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book21.707.518.045.67Net Income$12.01M-$55.05M$3.18B$249.13M7 Day Performance-1.95%4.61%2.82%3.30%1 Month Performance16.72%4.89%3.70%5.20%1 Year Performance62.88%5.84%35.41%21.38% Lifecore Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFCRLifecore Biomedical1.0508 of 5 stars$8.03-0.1%$8.00-0.4%+62.9%$297.68M$128.26M-5.54690GPCRStructure Therapeutics2.9478 of 5 stars$20.74-1.6%$76.17+267.2%-44.9%$1.21BN/A-23.84136CVACCureVac4.6374 of 5 stars$5.43+0.9%$6.83+25.8%+72.9%$1.21B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.2625 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.17B$235.13M30.25300Positive NewsBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298NAGENiagen Bioscience1.5267 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3715 of 5 stars$22.96-0.5%$32.33+40.8%-39.9%$1.09B$731.97M8.322,028News CoverageDYNDyne Therapeutics3.5058 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.09BN/A-2.65100ABCLAbCellera Biologics2.4905 of 5 stars$3.43-5.0%$8.33+143.0%+40.4%$1.08B$28.83M-6.12500High Trading VolumePAHCPhibro Animal Health3.6387 of 5 stars$25.54-0.5%$21.80-14.6%+63.3%$1.04B$1.02B32.741,940 Related Companies and Tools Related Companies Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors BGM Group Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFCR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
